DSM-5 ADHD

The DSM-5 ADHD fact sheet outlines updated criteria recognising ADHD as a lifelong condition, with revised age-of-onset, adult-specific guidance, and clarified diagnostic standards across all ages.

August 26, 2025

SNAP - IV Questionnaire

The SNAP-IV (Swanson, Nolan, and Pelham Rating Scale – Fourth Edition) is a behavioural questionnaire used to evaluate symptoms of ADHD (Attention Deficit Hyperactivity Disorder) and Oppositional Defiant Disorder (ODD) in children and adolescents.

July 4, 2025

ASRS Questionnaire

Adult ADHD Self-Report Scale (ASRS)

July 26, 2025

Example report - Shared Care Agreement

Example report template for ADHD medication increase

May 8, 2025

Example report template - Shared Care agreement (Coming Soon)

Example report template for Shared Care agreement

April 23, 2025

Example report template - Medication Travel Letter (Coming Soon)

Example report template for Medication Travel Letter

April 23, 2025

Choosing the First Medication for ADHD: Contextual Considerations for Clinicians

Selecting the initial medication for managing attention-deficit/hyperactivity disorder (ADHD) requires careful consideration of multiple contextual factors.

February 23, 2026

Understanding the Relationship Between ADHD and Anxiety Disorders

Attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with anxiety disorders, making it an important area for clinicians to understand.

February 23, 2026

Mental Restlessness in ADHD: The Hidden Symptom Many Adults Experience

When most people think about attention-deficit/hyperactivity disorder (ADHD), they picture visible behaviours such as fidgeting, restlessness, or difficulty sitting still.

February 20, 2026

Does Parenting Cause ADHD? A Science-Based Perspective

Discussions about the causes of attention-deficit/hyperactivity disorder (ADHD) often generate strong opinions.

February 20, 2026

Why Low-Tech Tools Often Work Better Than Apps for Adults With ADHD

When addressing difficulties with task organisation, planning, and follow-through in adults with ADHD, high-tech solutions are often recommended first. However, clinical experience and theory suggest that low-tech strategies are frequently more effective than app-based or “smart” solutions.

February 2, 2026

Maternal Diet During Pregnancy and Neurodevelopmental Risk: What Clinicians Need to Know

Recent research has reignited discussion around the role of maternal diet during pregnancy and the risk of neurodevelopmental conditions such as ADHD and autism spectrum disorder (ASD) in offspring.

February 2, 2026

Therapists – EMDR & CBT (ADHD Specialist)

Role: Remote Therapists (EMDR & CBT) Contract: Remote, Ad Hoc Pay: Competitive

Fully remote

ADHD Coach – Certified

Role: ADHD Coach Contract: Remote, Ad Hoc Pay: Competitive

Fully remote

ADOS Assessor – Remote

Role: ADOS Assessor (Autism Diagnostic Observation Schedule) Contract: Remote, Per Assessment Pay: £150 per assessment

Fully remote

Autism Assessor – ASD Specialist

Role: Autism Assessor (ASD – using ADOS framework) Contract: Remote, Ad Hoc (5–6 hours per week minimum) Pay: Competitive

Fully remote

Pharmacist – ADHD Prescriber

Role: Pharmacist (Remote Prescribing ADHD from age 6+) Contract: Remote, Ad Hoc (5–6 hours per week minimum) Pay: Competitive

Fully remote

ADHD Assessor Nurse

Role: ADHD Assessor – Registered Nurse Contract: Remote, Ad Hoc (5–6 hours per week minimum) Pay: Competitive

Fully remote

What are the key components of a comprehensive ADHD treatment plan beyond medication?

Medication is one aspect of a multimodal strategy. Psychoeducation, behavioural coaching, cognitive-behavioural therapy, sleep hygiene, exercise, and workplace adjustments all improve long-term outcomes. Encouraging structure and self-management strategies is vital for sustainable progress.

How often should follow-up reviews be conducted after initiating treatment?

During titration, reviews should occur every 2–4 weeks to assess efficacy, tolerability, and vital signs. Once stable, patients should be reviewed at least every 6 months, with documentation of symptom control, side-effects, adherence, and ongoing clinical need.

Can ADHD medication be prescribed alongside antidepressants or anxiolytics?

Yes, but review pharmacodynamic interactions carefully. SSRIs are generally safe with stimulants, but MAOIs are contraindicated. Monitor for additive effects on anxiety, blood pressure, and sleep. Start low, titrate gradually, and coordinate care with the prescribing GP or psychiatrist.

How should ADHD be managed in women presenting with hormonal fluctuations or perimenopausal symptoms?

Fluctuating oestrogen can affect dopamine and norepinephrine regulation, often worsening ADHD symptoms pre-menstrually or during perimenopause. Dose adjustments, switching to a longer-acting stimulant, or considering adjunctive HRT may be appropriate with multidisciplinary input.

What’s the current evidence on using ADHD medication in patients with substance misuse histories?

Stimulants can be used cautiously if substance use is stable and properly monitored. Lisdexamfetamine may carry a lower misuse potential due to its prodrug formulation. In active misuse, defer pharmacological treatment and focus on psychosocial interventions first.

How do you manage patients who report stimulant ‘crashes’ or rebound irritability?

Review dosing schedule first. Crashes may indicate too short a duration or excessive peak dose. Switching to a modified-release formulation or splitting doses can help. Also assess for poor sleep, caffeine use, or concurrent anxiety, which can exacerbate rebound effects.